The 6 Medical Device Commercialization Gaps That Kill Cleared Products Before Year Two Revenue Lands

Key Takeaways

• 35% of venture-backed medtech failures trace to market-definition problems, not product or capital problems, the second-largest cause after running out of cash
• The six commercialization gaps are: sales system transferability, outbound consistency, content-to-pipeline conversion, CRM and nurture infrastructure, sales assets and proof, and positioning clarity at scale
• Founders consistently misread these structural gaps as sales-team or fundraising problems and prescribe the wrong remedy
• Markets don't form on their own in medtech; they have to be engineered before launch, not captured after
• The companies that close all six gaps pre-launch see meaningfully better unit economics, faster rep ramp, and compounding pipeline within 12 months of commercial start

You're past clearance. The board signed off on the commercial plan. You hired a VP of Sales six months ago, a marketing director three months ago, and four reps in the last quarter.

The CRM is implemented. The content calendar is shipping. The KOL program has its first three named champions.

But revenue is at 30% of the original plan. Pipeline coverage is half of target. Rep ramp is taking three quarters longer than the comp plan modelled.

So the founder is being asked on the next board call to explain whether the team is the problem, whether the product needs more clinical data, or whether the company needs to raise a bridge to extend runway.

The actual diagnosis is usually none of those. It's that medical device commercialization runs through six structural gaps the company never closed pre-launch. This post lays out each gap, what closing it looks like operationally, and why founders consistently misread the gaps as sales or fundraising problems.

How Founders Misread Structural Gaps as Sales or Capital Problems

The first thing to fix in any medical device commercialization conversation is how founders read the symptoms. The default reading is wrong almost universally.

I covered the dynamic on an episode with Christopher about how cardiac intelligence platforms detect myocardial stress and heart failure early:

"Most founders and CEOs read that as a fundraising problem or a sales problem. It's not. It's a market problem. Markets don't form after launch, they form before it. And in medtech, they don't just form on their own, they have to be crafted and engineered."

So the symptoms (slow pipeline, missed quota, longer-than-modelled ramp) point upstream. The founder reading the symptoms as sales-execution problems prescribes more reps, more outbound, more content cadence. The founder reading them as fundraising problems prescribes a bridge round. Neither prescription addresses the structural gaps.

The structural gaps are six concrete pieces of medical device commercialization infrastructure that have to be in place before the commercial motion can compound. Each gap is fixable. But the remedy is upstream of the symptoms most founders are trying to address.

The Six Medical Device Commercialization Gaps

The six gaps come from the MarketCraft Market Blueprint methodology, derived from pattern analysis across the State of MedTech catalog and MarketCraft client engagements. Each gap maps to a specific operational deliverable the company needs in place before commercial scale.

Gap 1: Sales system transferability. The commercial motion runs entirely through the founder, with no documented playbook the rest of the sales team can execute. Every deal requires the founder in the room. The remedy is to document the script, the demo, the proof structure, and the objection handling that the founder has been doing intuitively. The deliverable is a playbook the next rep can execute without founder presence.

Gap 2: Outbound consistency and scale. The outbound motion is sporadic and undirected. Reps run outbound on whoever they remember to call this week. There's no named account list, no sequencing logic, no ownership over outbound performance. The remedy is a named-account strategy with weekly cadence accountability and quarterly review of which accounts moved through the funnel.

Gap 3: Content-to-pipeline conversion. The marketing team is producing content. The content is generating site traffic and form submissions. But the form submissions don't convert into pipeline because there's no system to route them, qualify them, and hand them to sales with the context the rep needs to advance the deal. The remedy is a documented lead-to-pipeline workflow that closes the loop between content engagement and sales conversation.

Gap 4: CRM and nurture infrastructure. Leads are being captured but not tracked consistently. Some leads live in the CRM. Some live in spreadsheets. Some live in individual rep notes. There's no nurture sequence routing leads who aren't sales-ready into a structured re-engagement motion. The remedy is a single source of truth (CRM) with documented nurture sequences for every lead state.

Gap 5: Sales assets and proof. The sales team is using improvised assets, decks they built themselves, case studies that exist as one-page word docs, ROI calculators built ad hoc per deal. There are no objection-handling frameworks, no productised case studies, no consistent narrative carriers. The remedy is a sales-enablement library with versioned, named, and managed assets the whole team uses.

Gap 6: Positioning clarity at scale. The internal team can articulate the positioning. But the external expression is inconsistent across the website, the deck, KOL conversations, conference booth materials, and analyst calls. Different team members tell different versions of the story. The remedy is a single positioning document the entire commercial team uses, plus an audit of every external surface to enforce consistency.

The Market-Definition Gap Underneath the Six

The six commercialization gaps don't exist in isolation. They sit on top of a deeper market-definition gap that, if unaddressed, makes every fix to the six gaps temporary.

I covered the market-definition problem on a recent solo episode about market engineering for medtech startups raising capital:

"Most MedTech founders don't exactly have a demand problem. What they have is really a definition problem. Until you really define a market clearly, you're not able to get any traction and your ability to get traction is going to determine your ability to raise capital."

So before any of the six gaps can close cleanly, the underlying market has to be defined. The founder needs a clear category, a named buyer, and a narrative the team can repeat.

If those three are missing, the commercialization gap work produces tactical improvements that don't compound because the foundation underneath them is shifting.

I also cited the venture-failure data on the same episode:

"Roughly 75% of venture-backed startups fail. When CB Insights ran the top reasons why startups fail, number one with 38% of it is they ran out of cash, and failed to raise new capital. After 38% of that, 35% of the startups in the second-largest failure category had a market-definition problem."

So 35% of medtech venture failures trace to market-definition issues. That's the second-largest failure category after running out of cash, which itself is often a downstream consequence of the market-definition problem. The companies that don't close the underlying market-definition gap end up in the cash-out category eventually.

Talent Is the Gap Multiplier

The six gaps and the underlying market-definition gap also depend on having the right commercial talent in place to close them. Strong product without strong commercial talent doesn't close any of the six.

I interviewed Paul LaViolette of SV Health Investors on an episode about medtech venture capital insights. Paul has invested across the medtech category for decades and named the talent dynamic clearly:

"You can always have a great technology but there's a lot of great technologies that fail you got to find like the people who can take it to Market and make it realized."

So the medical device commercialization gap work is also a talent question. The company has to recruit operators who have done this work before, ideally at companies that closed the same gaps successfully.

Founders who try to close the gaps with first-time commercial leaders typically need three to four years to ship what an experienced operator could ship in twelve to eighteen months.

Why Late-Stage Cybersecurity Compliance Becomes a Hidden Commercialization Gap

There's also a seventh gap that doesn't always show up in the standard six but kills the commercialization timeline when it materialises. Cybersecurity compliance issues discovered post-clearance can extend the launch timeline by months and cost over a quarter of a million dollars in remediation.

I interviewed Greg Lucier of Corza Medical on an episode about billion-dollar exits and his medtech acquisition game. Greg named the cybersecurity issue specifically:

"Scrambling to fix these issues last minute can cost over a quarter of a million dollars and delay your launch by months. The more you spend time in review limbo with the FDA is lost revenue, lost market share, and lost investor confidence."

The cybersecurity work is technically a regulatory-affairs gap rather than a commercial gap, but it sits squarely in the commercialization timeline because every month of delay is a month of commercial-team payroll burning against zero revenue.

Founders running the six-gap diagnostic should add a seventh check on cybersecurity readiness if the device has any networked component.

For more on the upstream category and market-engineering work that has to happen before the six gaps can close cleanly, see the medtech commercialisation strategy framework and the medtech go-to-market strategy playbook.

What This Means for Medtech Founders

In my experience working with medtech founders, the medical device commercialization conversation usually starts as a sales-performance conversation. The founder describes the symptoms (missed pipeline, slow rep ramp, low conversion) and asks for a sales fix.

The right diagnostic instead is to walk the six gaps with the team and identify which ones are genuinely closed.

So the better practice is to run the six-gap audit before the board reads the next quarter's results. The audit takes a week of leadership attention and surfaces which gaps are real, which are partial, and which are entirely missing.

The remediation work then targets the gaps in priority order rather than scattering across a dozen tactical sales-improvement initiatives that don't compound.

The companies that close all six gaps pre-launch are the companies that hit the unit economics and rep-ramp benchmarks the original commercial plan modelled.

The companies that hit clearance with multiple gaps still open spend the first 18 to 24 months post-launch closing the gaps as a recovery effort, which always costs more than closing them pre-launch would have.

Frequently Asked Questions

What is medical device commercialization?

Medical device commercialization is the set of disciplines required to move a cleared medical device from regulatory approval to scaled commercial revenue.

The work spans sales system design, outbound and inbound demand generation, marketing-to-sales handoff infrastructure, CRM and nurture systems, sales enablement assets, positioning consistency, and the underlying market-definition and category-design work that makes all of the above coherent.

Strong medical device commercialization plans close six structural gaps pre-launch rather than trying to close them as a post-launch recovery effort.

What are the most common medical device commercialization failures?

The most common failures are misdiagnosing structural gaps as sales-team or fundraising problems. The actual root causes are usually some combination of: undocumented sales motion that depends entirely on founder presence, inconsistent outbound execution, broken content-to-pipeline conversion, fragmented CRM and nurture infrastructure, improvised sales assets, and inconsistent positioning across external surfaces.

The underlying market-definition gap is what makes the surface-level gaps recur even after tactical fixes.

How long does medical device commercialization take to produce revenue?

For medtech companies that closed the six commercialization gaps pre-launch and have the underlying market-definition work in place, the first quarter of commercial revenue typically lands within 90 days of launch with predictable acceleration through quarter four.

Companies that hit launch with multiple gaps still open typically take 18 to 24 months to produce the same revenue trajectory because the post-launch period is consumed by gap-closing rather than commercial execution.

How does the commercialization gap framework connect to medtech venture failure data?

CB Insights data on venture-backed medtech failure attributes 38% of failures to running out of cash and 35% to market-definition problems. The two failure modes are connected: market-definition gaps drive slower-than-modelled commercial traction, which drives faster-than-modelled cash burn, which forces capital raises on weaker terms or company shutdown.

Closing the six commercialization gaps and the underlying market-definition gap pre-launch is the single highest-leverage move a medtech founder can make to avoid both failure modes.

Listen to the Full Conversations

The episodes referenced in this post are available on The State of MedTech. Subscribe wherever you listen to podcasts.

• How Cardiac Intelligence Platforms Detect Myocardial Stress & Heart Failure Early
• How Market Engineering Helps MedTech Startups Raise Capital
• Medtech Venture Capital Insights with Paul LaViolette of SV Health Investors
• Greg Lucier: Billion Dollar Exits and His Medtech Acquisition Game

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.